This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
28 May 2015

Award-Winning Cadence Inline Concentrator from Pall Life Sciences to be Showcased at ACHEMA 2015

Pall Corporation will showcase its Cadence Inline Concentrator (ILC) at ACHEMA 2015 in Frankfurt, Germany. Designed to simplify downstream processing, the Cadence Inline Concentrator was recently named Best in Show during the inaugural awards at INTERPHEX 2015 this April. It was selected as the winner for its unique ability to achieve continuous concentration of biomolecules in a single-pass mode, eliminating the recirculation loop traditionally associated with tangential flow filtration. Users report improved product recovery with optimized downstream processing (DSP) steps, reduced buffer usage, and lowered resin costs.



The Cadence ILC’s proprietary flow path comes with a pre-assembled module that does not require a holder, greatly reducing footprint, as well as work and hold-up volumes. The single pass-through design allows for continuous concentration with less protein shear.



“We were thrilled to have the Cadence Inline Concentrator selected as “Best in Show” by industry experts at INTERPHEX,” said Michael Egholm, President of Biopharmaceuticals at Pall Life Sciences. “This is a product that delivers results, and is unlike others on the market. Customers have recorded up to a 31% decrease in cost of goods sold, and up to 66% capital investment savings with the Cadence ILC. Wins like this keep our team focused on innovating solutions to continuously improve bioprocessing, and enable our customers to improve global health.”


The Cadence Inline Concentrator can be coupled with other DSP steps, including pre- and post-chromatography steps, continuous processing or in-line volume reduction, with typical applications including monoclonal antibodies, antibody fragments, recombinant proteins and other biological end products.

Related News